Long non-coding RNA: A recently accentuated molecule in chemoresistance in cancer.

Abstract

Chemotherapy is one of the important and effective options for cancer treatment in the past decades. Although the response rate of initial chemotherapy is considerably high in certain types of cancers, such as ovarian cancer and lung cancer, the patients frequently suffer from chemoresistance and recurrence of disease. Recent genome-wide studies have shown that the large number of long non-coding RNAs (lncRNAs) are transcribed from the human genome and involved in many biological processes including carcinogenesis. They aberrantly regulate variety of cell functions, such as cell cycle, apoptosis, autophagy, and metabolisms, which are associated with chemosensitivity. Therefore, understanding the biological and clinical impacts of lncRNAs on tumor behavior and its potential as a predictive biomarker for chemotherapy effectiveness is highly desired. In this review, we classify the major mechanisms of lncRNA-related chemoresistance and provide theoretical evidences for targeting lncRNAs in certain types of cancers that may open up new therapeutic paradigm for cancer treatment.

• Authors: Yang Peng, Dihong Tang, Meng Zhao, Hiroaki Kajiyama, Fumitaka Kikkawa, Yutaka Kondo
• Journal: Cancer metastasis reviews (Cancer Metastasis Rev) Vol. 39 Issue 3 Pg. 825-835 (09 2020) ISSN: 1573-7233 [Electronic] Netherlands
• PMID: 32594276 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• RNA, Long Noncoding

Topics

• Drug Resistance, Neoplasm
• Humans
• Molecular Targeted Therapy
• Neoplasms (drug therapy, genetics, metabolism)
• RNA, Long Noncoding (genetics, metabolism)